Ilyang Pharmaceutical Co.,Ltd
007570.KS · Korea Exchange · KRW
6.850,00KRW
+80,00 (+1,18 %)Stand 10. Nov., 6:30
Kennzahlen
- Eröffnung
- 6.900,00
- Vortag
- 6.770,00
- Tagesspanne
- 6.750,00 – 6.970,00
- 52 Wochen
- 6.500,00 – 16.240,00
- Volumen
- 13.218
- Ø Volumen
- 25.116
- Börsenwert
- 122,79 Mrd. KRW
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,4
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ind. Co. until its renaming in May 1991, primarily conducts its business in South Korea. It develops and provides a comprehensive portfolio of medicines addressing various therapeutic areas, such as oncology, cardiovascular health, endocrine and metabolic conditions, women's health (including female hormone treatments and cheonjiyang), urology, ophthalmology, liver diseases, pain and inflammation, digestive system issues, dermatological complaints, and respiratory illnesses. Their pharmaceutical offerings also extend to nutrient infusions, neurological medications, antibiotics, antifungals, insecticides, and vaccines. In addition to medicinal products, Ilyang manufactures a range of consumer health items, including health drinks, dietary supplements, health foods, cosmetics, and other beverages. The company is also a producer of numerous pharmaceutical raw materials, specifically various aluminum and magnesium compounds. Ilyang Pharmaceutical has an international footprint, exporting its diverse product range to roughly 14 countries worldwide.
- CEO
- Dong-Yeon Kim
- Mitarbeitende
- 665
- Hauptsitz
- Yongin, GY, KR
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 4. Jan. 2000
- Website
- ilyang.co.kr
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.